Punjab orders recall of five medicines over safety concerns AI-generated image

Punjab orders recall of five medicines over safety concerns

Newsora24 staff
2 minRead
0Views
0Reading now

The Government of Punjab has ordered the immediate recall of five pharmaceutical products after provincial drug testing laboratories found them substandard or adulterated. Authorities cited concerns about the quality and safety of the medicines.

A public notice issued by the Directorate of Drugs Control, Punjab, on November 13, 2026, said the Provincial Quality Control Board had directed that the affected batches be withdrawn from the market following laboratory testing.

Medicines and batches named in the recall

The notice identified the following products and batches:

  • Injection Dormicum, batches 47447 and 47661, made by Martin Dow Marker Ltd., declared substandard due to visible particulate matter
  • Injection Davilax, batch DD1126, made by Unison Chemical Works, declared adulterated
  • Injection Zeftrox, batch 677, made by Zafa Pharmaceutical Laboratories (Pvt.) Ltd., declared substandard after sterility testing
  • Injection PSOL 2mL, batch AK164, made by Pharmasol Private Ltd., declared substandard after sterility testing
  • Injection PSOL 10mL, batch VL277, made by Pharmasol Private Ltd., declared substandard due to visible particulate matter

Directives for manufacturers and pharmacies

The Directorate has instructed manufacturers and marketing authorisation holders to begin recall procedures immediately and provide complete distribution records for the identified batches. The companies have also been told to carry out detailed root-cause analyses and prepare Corrective and Preventive Action (CAPA) plans, which must be submitted to the relevant drug regulatory authorities.

Pharmacies, medical stores, wholesalers, distributors and healthcare facilities across Punjab have been directed to stop dispensing the affected batches at once. They must also report their remaining stock and consumption records to the area Drug Inspectors or Drug Inspectors of Health Facilities.

The Directorate has further directed the province’s drug regulators to strengthen surveillance across the pharmaceutical supply chain and take appropriate action under the Drugs Act, 1976, and the DRAP Act, 2012.

Advice for patients and reporting side effects

In an advisory to consumers and the public, the Directorate urged patients to stop using the identified batches immediately. It warned that continued use could pose health risks.

Healthcare professionals and consumers have been asked to report any adverse drug reactions linked to the affected products to the Provincial Pharmacovigilance Centre at the Directorate of Drugs Control, Punjab. The notice described the recall as part of the provincial government’s regulatory action to address pharmaceutical quality concerns and protect public health.

Leave an opinion

Your email address will not be published. Required fields are marked *

Story saved